
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort Inc. reported a total revenue of $44 million, reflecting a 15% year-over-year growth in constant currency terms, which indicates a slight improvement from the previous quarter's growth rate of 14%. The company benefits from an increasing number of gene therapy programs across various stages, particularly in oncology and rare diseases, bolstering expectations for both commercial revenue and clinical trial activity. The positive momentum is further reinforced by the growing acceptance of cell and gene therapies in the market, driving a consistent upward trajectory in approved therapies and pipeline developments.
Bears say
CryoPort Inc. is experiencing a decline in funding for start-ups within its sector, which may adversely impact future growth and innovation, thereby creating a negative outlook for the company. Despite a 16% growth in Life Sciences Services revenue to $24 million, this growth rate has slowed compared to the previous quarter, and the adjusted EBITDA margin remains negative at (1.5%), which indicates persistent profitability challenges. Moreover, anticipated decreases in cell and gene therapy approvals, combined with a slowdown in demand for MVE freezers, contribute to the company's downward revisions in earnings per share for 2026.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares